Mohamed Benchekroun

Picture mars 2020


Dr. Mohamed Benchekroun holds a Master in Organic Chemistry (2010, Université Paris-Sud) and a Doctorate in Medicinal Chemistry (2014, Université de Franche-Comté). In 2015-2016, he did a postdoctoral stay at the Institut de Chimie des Substances Naturelles (Dr. Robert H. Dodd, Dr. Kevin Cariou, ICSN-CNRS) where he was involved in the discovery of new β-lactamases inhibitors to fight bacterial resistance. From 2016 to 2018, he worked at the Sussex Drug Discovery Centre under the guidance of Prof. Simon Ward and Prof. John Atack. During this period, he participated to the discovery of new modulators of the GABAA receptors for the treatment of anxiety without sedative effects. After one year back in 2018-2019 at the ICSN-CNRS, working with Dr. Ali Al-Mourabit on new necroptosis inhibitors, he moved to the Conservatoire National des Arts et Métiers in the group of Prof. Marc Port (Paris, France) where he is involved in the discovery of innovative cytokines small-molecule modulators. Mohamed has a diverse experience in the discovery and lead optimization of bioactive small molecules targeting diseases with high unmet medical needs (neurodegeneratives/neurological diseases, inflammatory diseases, infectious diseases, cancer).

drug-icon-2316244_1280.pngTélécharger le CV complet de Mohamed Benchekroun (pdf)